Company intelligence / Profile preview

Novasep

Ownership: Private
Employees: ~1250
Development stage: Commercial

Overview

Novasep is an established European CDMO specializing in the production and purification of complex small molecules, antibody-drug conjugates, biologics, and other fine chemicals. It provides contract manufacturing services as well as process development and equipment solutions to pharmaceutical, biopharmaceutical, agrochemical, and fine chemical industries. The company has undergone significant transformation in recent years—divesting its viral vector business to Thermo Fisher Scientific in 2021—and merged with PharmaZell in 2022 to form a leading global API/CDMO group backed by Bridgepoint Group PLC.

Modalities: Small moleculeAntibody-drug conjugateBiologic
Industry: Contract Manufacturing Organization

Beyond the preview

Go deeper on Novasep.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novasep.

Explore the full profile